In Brief: Research Medical
This article was originally published in The Gray Sheet
Executive SummaryResearch Medical: Plans to unveil its disposable beating heart minimally invasive cardiac surgery product line at the February 1997 Society of Thoracic Surgeons Meeting in San Deigo. The line includes the Anastaflo intravascular shunt for insertion into both ends of the severed coronary artery to prevent excess blood loss and the Visuflo humidified air blower with light source for lighting and removal of unwanted blood, both of which have been cleared by FDA. In addition, a "heart elevator" to minimize movement during bypass, a "stabilizing suction wand" to immobilize the section of heart operated on, and a femoral-to-arterial shunt to provide femoral artery blood flow to regions below the grafting site are expected to be 510(k) cleared in early 1997. The Midvale, Utah-based firm says Anastaflo and Visuflo will be commercially available by the end of the current quarter, with the other three devices expected to reach the market in June 1997...
You may also be interested in...
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.